このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

子宮内膜がん患者の拡大を伴うHER2発現がんにおけるDS-8201aとオラパリブの組み合わせのテスト

2026年11月11日 更新者:National Cancer Institute (NCI)

HER2発現悪性腫瘍におけるオラパリブと組み合わせたDS-8201aの第I相試験

This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component and a chemotherapy component. The antibody component is attached to the chemotherapy molecules. Upon administration of DS-8201a, the antibody targets and binds to tumor cells that have abundant HER2 (human-epidermal growth factor receptor 2), which is a protein on the surface of some tumor cells. The chemotherapy then enters the cells and blocks deoxyribonucleic acid (DNA) replication in the tumor cells with abundant HER2, causing them to die. Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. Giving DS-8201a and olaparib may shrink or stabilize the cancer.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of the combination of trastuzumab deruxtecan (DS-8201a) in combination with olaparib, and to determine the recommended phase 2 dose (RP2D).

II. To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with platinum resistant high grade serous ovarian carcinoma.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity as measured by objective response rate (ORR), clinical benefit rate, progression-free survival (PFS), and duration of response (DoR).

II. To measure baseline HER2 expression by immunohistochemistry (IHC) in a central laboratory and correlate with response in the dose escalation and in the dose expansion.

III. To evaluate the plasma pharmacokinetic (PK) profiles of olaparib and DS-8201a metabolites when administered in combination in the dose escalation and in the dose expansion.

IV. To determine markers of DNA damage response (DDR) in tumor specimens at baseline and on-treatment in patients with platinum resistant high grade serous ovarian carcinoma in dose expansion.

EXPLORATORY OBJECTIVES:

I. To measure baseline HER2 expression by immune multiple reaction monitoring-mass spectroscopy (ImmunoMRM), and correlate with baseline central IHC and with response in dose escalation and in dose expansion.

II. To assess the formation of topoisomerase I cleaved complex formation (TOP1cc) in blood specimens and correlate with response in dose escalation and in dose expansion.

III. To assess the formation of TOP1cc in paired on-treatment tumor specimens (after DS-8201a alone and after DS-8201a and olaparib combination) and correlate with response in patients with platinum resistant high grade serous ovarian carcinoma in the expansion.

IV. To measure changes in HER2 expression over the course of treatment by IHC and immunoMRM and correlate with response in patients with platinum resistant high grade serous ovarian carcinoma in dose expansion.

V. To determine biomarkers of response and resistance in tumor specimens and blood specimens, including whole exome sequencing (WES) and ribonucleic acid (RNA) sequencing.

OUTLINE: This is a dose-escalation study of trastuzumab deruxtecan in combination with olaparib followed by a dose-expansion study.

Patients receive trastuzumab deruxtecan intravenously (IV) over 30-90 minutes on day 1 and olaparib orally (PO) twice daily (BID) on days 1-21, days 8-14, or days 3-9 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. All patients undergo collection of blood samples, echocardiography (ECHO) or multigated acquisition scan (MUGA), computed tomography (CT), and biopsies throughout the trial.

After completion of study treatment, patients are followed up for 30 days.

研究の種類

介入

入学 (推定)

55

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85054
        • 積極的、募集していない
        • Mayo Clinic Hospital in Arizona
    • Florida
      • Coral Gables、Florida、アメリカ、33146
        • 募集
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
        • コンタクト:
          • Site Public Contact
          • 電話番号:305-243-2647
        • 主任研究者:
          • Abdulrahman Sinno
      • Deerfield Beach、Florida、アメリカ、33442
        • 募集
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
        • コンタクト:
          • Site Public Contact
          • 電話番号:305-243-2647
        • 主任研究者:
          • Abdulrahman Sinno
      • Doral、Florida、アメリカ、33166
        • 募集
        • UM Sylvester Comprehensive Cancer Center at Doral
        • 主任研究者:
          • Abdulrahman Sinno
        • コンタクト:
      • Jacksonville、Florida、アメリカ、32224-9980
        • 募集
        • Mayo Clinic in Florida
        • コンタクト:
          • Site Public Contact
          • 電話番号:855-776-0015
        • 主任研究者:
          • Andrea E. Wahner Hendrickson
      • Miami、Florida、アメリカ、33136
        • 募集
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • コンタクト:
          • Site Public Contact
          • 電話番号:305-243-2647
        • 主任研究者:
          • Abdulrahman Sinno
      • Miami、Florida、アメリカ、33176
        • 募集
        • UM Sylvester Comprehensive Cancer Center at Kendall
        • コンタクト:
          • Site Public Contact
          • 電話番号:305-243-2647
        • 主任研究者:
          • Abdulrahman Sinno
      • Plantation、Florida、アメリカ、33324
        • 募集
        • UM Sylvester Comprehensive Cancer Center at Plantation
        • コンタクト:
          • Site Public Contact
          • 電話番号:305-243-2647
        • 主任研究者:
          • Abdulrahman Sinno
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Emory University Hospital/Winship Cancer Institute
        • 主任研究者:
          • Kristen Starbuck
        • コンタクト:
          • Site Public Contact
          • 電話番号:404-778-1868
      • Atlanta、Georgia、アメリカ、30308
        • 募集
        • Emory University Hospital Midtown
        • 主任研究者:
          • Kristen Starbuck
        • コンタクト:
          • Site Public Contact
          • 電話番号:888-946-7447
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana-Farber Cancer Institute
        • コンタクト:
          • Site Public Contact
          • 電話番号:877-442-3324
        • 主任研究者:
          • Elizabeth K. Lee
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic in Rochester
        • コンタクト:
          • Site Public Contact
          • 電話番号:855-776-0015
        • 主任研究者:
          • Andrea E. Wahner Hendrickson
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • 募集
        • UPMC Hillman Cancer Center
        • コンタクト:
          • Site Public Contact
          • 電話番号:412-647-8073
        • 主任研究者:
          • Sarah E. Taylor

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • DOSE ESCALATION PHASE:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

  • Patients must have HER2-positive or HER2-expressing tumors determined by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory. Specific requirement of HER2 status is outlined below:

    • Dose Escalation Module 1 and Module 2:

      • HER2 1-3+ expression by IHC OR
      • HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
      • If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible
    • Dose Escalation Module 3:

      • HER2 1-2+ expression by IHC OR
      • HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
      • If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible
  • DOSE EXPANSION PHASE:

  • Patients must have histologically confirmed platinum resistant, high grade serous ovarian carcinoma. Platinum resistant is defined as radiographic progression < 6 months following the last dose of platinum therapy

  • HER2 IHC 1+ per local or central testing

  • There must be least one lesion suitable for biopsy without significant risk to the patient

  • Patient disease must be evaluable or measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Biopsiable lesion cannot be the only RECIST-measurable lesion

  • DOSE ESCALATION AND DOSE EXPANSION PHASES:

  • Patients must have had at least one prior line of cytotoxic chemotherapy

  • Patients can have received an unlimited number of additional lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy

  • Patients must have archival formalin-fixed paraffin-embedded (FFPE) tissue available for central confirmation of HER2 testing

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of DS-8201a in combination with olaparib in patients < 18 years of age, children are excluded from this study

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Hemoglobin >= 10.0 g/dL (within 21 days of randomization/enrollment)

    • No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment
  • Absolute neutrophil count >= 1,000/mcL (within 21 days of randomization/enrollment)

    • No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment
  • Platelets >= 100,000/mcL (within 21 days of randomization/enrollment)

    • No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (< 3 x ULN in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 21 days of randomization/enrollment)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (within 21 days of randomization/enrollment)

  • Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 (using the Cockcroft-Gault Equation) (within 21 days of randomization/enrollment)

  • Patients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization/enrollment

  • Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:

    • They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective
    • They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 7 days of enrollment
    • They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
    • HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with brain metastases should be stable and off steroids and at least 4 weeks from radiation at the time of registration

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be better than class 2B

  • The effects of DS-8201a and olaparib on the developing human fetus are unknown. For this reason and because HER2 antibody conjugated to a topoisomerase 1 inhibitor agents as well as PARP inhibitors are known to be teratogenic; thus, women of child-bearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 7 months (women of childbearing potential [WOCBP] only) after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a and olaparib administration

  • Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method

  • Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study

  • Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration

  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have had chemotherapy (including antibody drug therapy) within 4 weeks with the following exceptions: 1 week for weekly paclitaxel; 2 weeks or five half-lives, whichever is longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, hormonal agents; or 6 weeks for nitrosoureas or mitomycin C
  • Patients who have had radiation therapy within 4 weeks
  • Patients who have had a major surgery within 4 weeks
  • Patients who are receiving any other investigational agents
  • Patients with a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Patients with clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e. rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a, the inactive ingredients in the drug product, olaparib, or severe hypersensitivity to other monoclonal antibodies
  • Patients receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Patients with a medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association class IIb to IV), troponin levels consistent with myocardial infarction as defined according to the manufacturer 28 days prior to randomization
  • Patients with a corrected QT interval (QTc) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram (ECG)
  • Patients with multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors curatively treated
  • Patients with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Patients receiving chloroquine or hydroxychloroquine will require a washout period of >= 14 days to be eligible for the study
  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade =< 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the investigator after consultation with the sponsor medical monitor or designee (e.g., grade 2 chemotherapy-induced neuropathy)
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because DS-8201a is a HER2 antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a. These potential risks may also apply to other agents used in this study
  • Patients who have received a live, attenuated vaccine within 30 days prior to the first dose of DS-8201a

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (trastuzumab deruxtecan, olaparib)

Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21, days 8-14, or days 3-9 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. All patients undergo collection of blood samples, ECHO or MUGA, CT, and biopsies throughout the trial.

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo MUGA

他の名前:
  • 血液プールスキャン
  • 平衡放射性核種血管造影
  • ゲーテッド血液プールイメージング
  • ムガ
  • 放射性核種心室造影
  • RNVG
  • SYMAスキャン
  • 同期マルチゲート取得スキャン
  • ムガスキャン
  • マルチゲート取得スキャン
  • 放射性核種脳室造影スキャン
  • ゲーテッドハートプールスキャン
  • RNVスキャン

Undergo biopsy

他の名前:
  • Bx
  • BIOPSY_TYPE
  • 生検

Undergo collection of blood samples

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Given PO

他の名前:
  • リムパーザ
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP阻害剤AZD2281
  • KU0059436
  • オラニブ
  • オラパリクス
  • KU 0059436

Undergo echocardiography

他の名前:
  • 心エコー検査
  • EC

Given IV

他の名前:
  • エンヘルトゥ
  • DS-8201a
  • T-DXd
  • DS-8201
  • ファムトラスツズマブ
  • WHO 10516

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
有害事象の発生率
時間枠:治療後30日まで
治療後30日まで
Maximum tolerated dose/recommended phase 2 dose
時間枠:Up to 42 days

Will be measured by Common Terminology Criteria for Adverse Events version (v) 5.0 and analyzed using descriptive statistics.

Up to 42 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective response rate (ORR)
時間枠:Up to 30 days post treatment

ORR will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria to determine the best overall response for evaluable patients.

Up to 30 days post treatment
Clinical benefit rate (CBR)
時間枠:Up to 30 days post treatment

CBR will be evaluated by RECIST 1.1 criteria to determine the best overall response for evaluable patients.

Up to 30 days post treatment
Duration of response (DOR)
時間枠:Up to 30 days post treatment

DOR will be evaluated by RECIST 1.1 criteria to determine the best overall response for evaluable patients. DOR will be described using the method of Kaplan-Meier.

Up to 30 days post treatment
HER2 expression
時間枠:At baseline

HER2 expression on archival specimens will be analyzed using current American Society of Clinical Oncology/College of American Pathologists breast cancer and gastric cancer scoring methods. The levels of HER2 expression (0, 1+, 2+, or 3+) will be determined and the number and percentage of patients in each category will be reported. Chi-squared test and regression modeling may be used to investigate any possible relationship of HER2 biomarker levels with anti-tumor efficacy.

At baseline
Plasma pharmacokinetic (PK) profiles
時間枠:Up to 30 days post treatment

PK will be analyzed using descriptive statistics. Analysis of variance and regression model may be used to investigate any possible relationship of PK biomarker levels with anti-tumor efficacy

Up to 30 days post treatment
Markers of deoxyribonucleic acid (DNA) damage response (DDR)
時間枠:At baseline and on-treatment

Markers of DDR will be measured by multiplex IF in tumor specimens at baseline and on-treatment in patients with platinum resistant high grade serous ovarian carcinoma in the dose expansion cohort and correlating these markers with response. For the DDR assay, levels exceeding 4% nuclear area positive (NAP) γH2AX, 4% NAP pNBS1, and 5% cells with ≥ 5 Rad51 nuclear foci indicate a DNA damage activation response (Wilsker et al., 2019).

At baseline and on-treatment

その他の成果指標

結果測定
メジャーの説明
時間枠
HER2 expression
時間枠:Up to 30 days post treatment

Correlation between HER2 expression, immunohistochemistry (IHC), and response may be evaluated by Chi-squared test and regression model.

Up to 30 days post treatment
Formation of topoisomerase I cleaved complex formation (TOP1cc) in blood samples
時間枠:Up to 30 days post treatment

Will measure the formation of formation TOP1cc in blood specimens and correlate with response in the dose escalation and in the dose expansion Will be analyzed using descriptive statistics.

Up to 30 days post treatment
Presence of topoisomerase I cleaved complex formation (TOP1cc) in paired on-treatment tumor specimens
時間枠:Up to 30 days post treatment

Will assess the presence of TOP1cc in paired on-treatment tumor specimnes and correlate with response in patients with platinum resistant high grade serous ovarian carcinoma in the dose expansion. Will be analyzed using descriptive statistics.

Up to 30 days post treatment
Changes in HER2 expression
時間枠:Baseline up to 30 days post treatment

Will measure changes in HER2 expression over the course of treatment by IHC and immunoMRM and correlate with response in patients with platinum resistant high grade serous ovarian carcinoma in the dose expansion. Will be analyzed using descriptive statistics.

Baseline up to 30 days post treatment
Biomarkers of response and resistance
時間枠:Up to 30 days post treatment

Will be analyzed using descriptive statistics.

Up to 30 days post treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Elizabeth K Lee、Dana-Farber - Harvard Cancer Center LAO

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年5月21日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2020年10月13日

QC基準を満たした最初の提出物

2020年10月13日

最初の投稿 (実際)

2020年10月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2020-07841
  • UM1CA186709 (米国 NIH グラント/契約)
  • NCI-2020-07841 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • 10355 (その他の識別子:CTEP)
  • 10355 (その他の識別子:Dana-Farber - Harvard Cancer Center LAO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する